Carl O Landgren, MD

Trials

Studies that name Carl O Landgren, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:59 UTC. Open this list on ClinicalTrials.gov

• N/A
  NCT07446777 · FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

  University of Miami · recruiting · Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma · principal investigator
• Ph2
  NCT06997081 · ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)

  University of Miami · recruiting · Multiple Myeloma · principal investigator
• Ph2
  NCT06100237 · Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

  Carl Ola Landgren, MD, PhD · recruiting · Multiple Myeloma · principal investigator
• Ph2
  NCT05896228 · Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

  Benjamin T Diamond, MD · recruiting · Refractory Multiple Myeloma, Relapsed Multiple Myeloma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.